Phase Ib study of the combination of pexidartinib (PLX3397), a CSF-1R inhibitor, and paclitaxel in patients with advanced solid tumors

PURPOSE: To evaluate the safety, recommended phase II dose (RP2D) and efficacy of pexidartinib, a colony stimulating factor receptor 1 (CSF-1R) inhibitor, in combination with weekly paclitaxel in patients with advanced solid tumors. PATIENTS AND METHODS: In part 1 of this phase Ib study, 24 patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Wesolowski, Robert, Sharma, Neelesh, Reebel, Laura, Rodal, Mary Beth, Peck, Alexandra, West, Brian L., Marimuthu, Adhirai, Severson, Paul, Karlin, David A., Dowlati, Afshin, Le, Mai H., Coussens, Lisa M., Rugo, Hope S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6589951/
https://www.ncbi.nlm.nih.gov/pubmed/31258629
http://dx.doi.org/10.1177/1758835919854238

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6589951/
https://www.ncbi.nlm.nih.gov/pubmed/31258629
http://dx.doi.org/10.1177/1758835919854238

Ejemplares similares